Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
|
|
|
- CAS號:
- 2055362-72-4
- 英文名:
- Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
- 英文別名:
- ADH-503 free base;Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-;ADH503,orally,macrophages,repolarization,dendritic,ADH 503,Complement System,allosteric,ADH-503,CD11b,tumorassociated,(Z)Leukadherin1,Inhibitor,(Z) Leukadherin 1,tumor-infiltrating,inhibit,immunosuppressive
- 中文名:
- Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
- 中文別名:
- 化合物 T13379;化合物(Z)-LEUKADHERIN-1
- CBNumber:
- CB85488502
- 分子式:
- C22H15NO4S2
- 分子量:
- 421.49
- MOL File:
- 2055362-72-4.mol
|
|
|
Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-化學性質(zhì)
-
沸點:
-
634.7±65.0 °C(Predicted)
-
|
-
密度:
-
1.50±0.1 g/cm3(Predicted)
-
|
-
儲存條件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
形態(tài):
-
Solid
-
|
-
酸度系數(shù)(pKa):
-
4.11±0.10(Predicted)
-
|
-
顏色:
-
Light yellow to yellow
-
|
Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-性質(zhì)、用途與生產(chǎn)工藝
(Z)-Leukadherin-1 (ADH-503 free base) 是一種具有口服活性的，變構(gòu)的 CD11b 激動劑。(Z)-Leukadherin-1 可以導致與腫瘤相關的巨噬細胞重新極化，減少腫瘤浸潤性免疫抑制骨髓細胞的數(shù)量，并增強樹突狀細胞的反應。
(Z)-Leukadherin-1 (ADH-503 free base; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b
+
cells and subsets of CD11b
+
monocytes, granulocytes, eosinophils, and macrophages.
(Z)-Leukadherin-1 (ADH-503 free base; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
(Z)-Leukadherin-1 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.
|
Animal Model:
|
KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras
G12D
/p53
flox/flox
]
|
|
Dosage:
|
30, 60, or 120 mg/kg
|
|
Administration:
|
Oral gavage; 60 days
|
|
Result:
|
Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
|
|
Animal Model:
|
Male rats
|
|
Dosage:
|
30, 100 mg/kg (Pharmacokinetic Analysis)
|
|
Administration:
|
Oral gavage twice a day; on days 1 and 5
|
|
Result:
|
Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.
|
Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
生產(chǎn)廠家
2055362-72-4, Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]- 相關搜索:
- 抑制劑
- 化合物(Z)-LEUKADHERIN-1
- 化合物 T13379
- 2055362-72-4
- ADH503,orally,macrophages,repolarization,dendritic,ADH 503,Complement System,allosteric,ADH-503,CD11b,tumorassociated,(Z)Leukadherin1,Inhibitor,(Z) Leukadherin 1,tumor-infiltrating,inhibit,immunosuppressive
- ADH-503 free base
- Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-